Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck pifeltro (doravirine — HIV-1 NNRTI) — Worldwide reported growth YoY (%) (%)
Form 8-K Table 3 / 3a / 3b Product Sales
Latest, Q4 2025
6.0%
Period ended Dec 31, 2025
Change on a year earlier
-14.0 pts
20.0% in Q4 2024
History
8 quarters
Since Q1 2024
Sources
8
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Pifeltro (doravirine — HIV-1 NNRTI) — Worldwide reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q4 2025 | Dec 31, 2025 | 6.0% | -14.0 pts | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| Q3 2025 | Sep 30, 2025 | 1.0% | -13.0 pts | Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗ |
| Q2 2025 | Jun 30, 2025 | 5.0% | +2.0 pts | Form 8-K (tm2521736d1_ex99-1.htm, filed 2025-07-29) ↗ |
| Q1 2025 | Mar 31, 2025 | 7.0% | -16.0 pts | Form 8-K (tm2512885d1_ex99-1.htm, filed 2025-04-24) ↗ |
| Q4 2024 | Dec 31, 2024 | 20.0% | – | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| Q3 2024 | Sep 30, 2024 | 14.0% | – | Form 8-K (tm2426878d1_ex99-1.htm, filed 2024-10-31) ↗ |
| Q2 2024 | Jun 30, 2024 | 3.0% | – | Form 8-K (tm2420272d1_ex99-1.htm, filed 2024-07-30) ↗ |
| Q1 2024 | Mar 31, 2024 | 23.0% | – | Form 8-K (tm2412490d1_ex99-1.htm, filed 2024-04-25) ↗ |
Cite this data
StockData. (2026). Merck Pifeltro (doravirine — HIV-1 NNRTI) — Worldwide reported growth YoY (%) (%), quarterly Q1 2024–Q4 2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_pifeltro_ww_nom_yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.